Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib +/- Panobinostat in Pediatric DIPG
NCT04341311Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of marizomib in diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Dose-limiting toxicity at 28 Days, Maximum Tolerated Dose at 28 Days and 5 more. Started Aug 2020; status: terminated.
02
Drugs
marizomib
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT04341311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341311.